Cardiff Oncology to Participate in September 2026 Conferences

Cardiff Oncology to Present at Two September 2026 Conferences on PLK1 Inhibition and RAS Mutant Cancer Therapies

Cardiff Oncology announced that their Ph.D. Mani Mohindru will present at the 8th Annual RAS-Targeted Drug Development Summit and participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference. The company focuses on developing PLK1 inhibition therapies, including its lead candidate onvansertib, targeting RAS-mutated metastatic colorectal cancer and other PLK1-driven cancers. Presentation materials and webcasts will be available for investors and interested parties.

Cardiff Oncology to Participate in September 2026 Conferences

CRDF

Summarize with

ChatGPT Perplexity Claude Grok Gemini

Key Points

Cardiff Oncology will present on advancing PLK1 targeted therapies in RAS mutant metastatic colorectal cancer at a major drug development summit.
The company will participate in an investor-focused fireside chat at the H.C. Wainwright Global Investment Conference.
Onvansertib, a lead oral PLK1 inhibitor, is currently in Phase 2 trials targeting hard-to-treat cancers with high unmet medical need.
Impacted sectors include biotechnology, pharmaceuticals, oncology research, and healthcare innovation.

SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that Mani Mohindru, Ph.D. will participate in two upcoming conferences.

Details of the company’s participation are as follows:

8th Annual RAS-Targeted Drug Development Summit
- Advancing PLK1 Targeted Therapy to Transform Outcomes in RAS Mutant Metastatic Colorectal Cancer; Tuesday, September 8 at 9:00 AM ET
H.C. Wainwright 28th Annual Global Investment Conference
- Fireside Chat; Monday, September 14 at 10:00 AM ET

After the conclusions of these events, interested parties can access slides by visiting the “Events” section of the Cardiff Oncology website. In addition, for the H.C. Wainwright conference, interested parties can register for and access the live webcast for the conference by visiting the “Events” section of the Cardiff Oncology website. That webcast replay will be available after the conclusion of the presentation.

About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company advancing innovative cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Our lead asset, onvansertib, is a highly specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (“mCRC”), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single-agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, we aim to overcome treatment resistance and deliver improved clinical outcomes for patients.

For more information, please visit https://www.cardiffoncology.com.

Investor Contact: 
Candice Masse 
Astr Partners 
[email protected] 

Media Contact:
Amy Bonanno
Lyra Strategic Advisory
[email protected]

Risks

Clinical-stage development implies ongoing trial and regulatory risks for onvansertib and other pipeline drugs, with uncertain outcomes.
Market interest may depend on tangible clinical data or results beyond conference presentations, making information dissemination a potential limiting factor.
Competition from other oncology drug developers targeting similar pathways or mechanisms could impact Cardiff Oncology's market potential and investment appeal.

Menu

Cardiff Oncology to Participate in September 2026 Conferences

Key Points

Risks

More from Press Releases